[Federal Register Volume 68, Number 45 (Friday, March 7, 2003)]
[Notices]
[Page 11113]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-5394]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30DAY-23-03]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
the CDC Reports Clearance Officer at (404) 498-1210. Send written 
comments to CDC, Desk Officer, Human Resources and Housing Branch, New 
Executive Office Building, Room 10235, Washington, DC 20503. Written 
comments should be received within 30 days of this notice.
    Proposed Project: Evaluating the Impact of Lymphedema and a 
Lymphedema Management Intervention for Women with Lymphatic Filariasis: 
Understanding Issues Related to Quality of Life--New--National Center 
for Infectious Diseases (NCID), Centers for Disease Control and 
Prevention (CDC). Lymphatic filariasis, a mosquito-transmitted 
parasitic disease affecting over 120 million people, is the second 
leading cause of permanent disability worldwide. Globally, lymphatic 
filariasis causes debilitating genital disease in an estimated 25 
million men and lymphedema or elephantiasis of the leg in 15 million 
people, mostly women in poverty stricken countries. The World Health 
Organization (WHO) recently identified community management of chronic 
lymphedema as one of the top twenty lymphatic filariasis research 
priorities. Recent advances in the management of chronic lymphedema 
include a prescribed hygiene and wound care intervention. This 
intervention has shown promising results in preventing bacterial 
infections thus reducing acute attacks, and anecdotally improving 
overall quality of life, alleviating pain and preventing further 
suffering.
    This pilot study will provide a micro-level perspective of women's 
own experiences of living with lymphedema and others responses to it, 
illuminating the nature of the disease, the vulnerability of those 
disabled by the disease, and the impact of an intervention to influence 
the consequences of having the disease. This study will provide a 
better understanding, through a combination of qualitative and 
quantitative methods, the influence of lymphadema as well as the 
efficacy of a lymphedema management intervention in reducing episodes 
of bacterial infections and improving quality of life in women with 
lymphedema in two developing countries.
    Women will be queried through in-depth interviews, focus groups, 
and questionnaire surveys as to the influence of lymphadema on their 
lives. Quality of life domains that will be explored include physical 
health, psychological health, social relationships, economic 
productivity, spiritual health, stigma, and environment. 
Recommendations will be derived from this study for the global 
community of lymphatic filariasis researchers in developing countries 
initiating national and local programs for the management of chronic 
lymphedema. There are no costs to respondents.

----------------------------------------------------------------------------------------------------------------
                                                                                                      Average
                                                                     Number of       Number of        burden/
                              Forms                                 respondents     responses/     response  (in
                                                                                    respondent        hours)
----------------------------------------------------------------------------------------------------------------
In-depth Survey at Sites A and B................................              50               1           60/60
Cross-sectional Survey at Sites A and B.........................             200               1           60/60
----------------------------------------------------------------------------------------------------------------


    Dated: February 28, 2003.
Thomas Bartenfeld,
Acting Associate Director for Policy, Planning and Evaluation, Centers 
for Disease Control and Prevention.
[FR Doc. 03-5394 Filed 3-6-03; 8:45 am]
BILLING CODE 4163-18-P